Emibetuzumab

Drug Profile

Emibetuzumab

Alternative Names: c-MET monoclonal antibody - Eli Lilly; cMET antibody - Eli Lilly; LA-480; LY-2875358

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Proto oncogene protein c met inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer; Non-small cell lung cancer
  • Phase I/II Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for phase-I development in Cancer(Combination therapy) in Japan (IV)
  • 15 Mar 2016 Biomarkers information updated
  • 20 Mar 2015 Eli Lilly and Innovent agree to co-promote and co-develop emibetuzumab in China for Non-small cell lung cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top